Skip to main content
Premium Trial:

Request an Annual Quote

Celera and Ipsen to Develop Biomarkers, PGx Tests for Growth Failure Therapies

NEW YORK (GenomeWeb News) - Celera will help Ipsen develop pharmacogenomic tests that could be used in tandem with Ipsen’s hormone-replacement therapies for short stature, the companies said yesterday.
 
Under the first phase of the multi-year collaboration, Celera will work with the Paris-based specialty pharmaceutical company to locate and characterize genetic markers related to growth failure.
 
Should those efforts produce successful results, the companies will then develop diagnostic predictors that Ipsen could use in clinical trials. These predictors would then “potentially form the basis for commercial companion diagnostic tests for Ipsen's short stature therapies,” the companies said.
 
Ipsen will pay Celera an undisclosed sum for the initial phase of the collaboration. Any future payments will depend on the success of the initial phase.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.